{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:16:12Z","timestamp":1791249372458,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaad.2019.06.035","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T16:54:55Z","timestamp":1561136095000},"page":"311-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events"],"prefix":"10.1016","volume":"82","author":[{"given":"Linda","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley J.E.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Byth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merribel","family":"Kyaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fernandez-Penas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jaad.2019.06.035_bib1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2015.2274","article-title":"Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy","volume":"1","author":"Lo","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2019.06.035_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.jaad.2019.06.035_bib3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2019.06.035_bib4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2019.06.035_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2019.06.035_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2019.06.035_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jaad.2019.06.035_bib8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.jaad.2019.06.035_bib9","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2019.06.035_bib10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2019.06.035_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.06.035_bib12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ad.2016.05.019","article-title":"Cutaneous adverse events of new anti-melanoma therapies: classification and management","volume":"108","author":"Hwang","year":"2017","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"10.1016\/j.jaad.2019.06.035_bib13","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jaad.2019.06.035_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo-like depigmentation with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.06.035_bib15","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"14","key":"10.1016\/j.jaad.2019.06.035_bib16","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.jaad.2019.06.035_bib17","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1038\/sj.jid.5700545","article-title":"Enhanced survival associated with vitiligo-like depigmentation expression during maintenance biotherapy for metastatic melanoma","volume":"126","author":"Boasberg","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.06.035_bib18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/ije\/dyu105","article-title":"Avoiding blunders involving 'immortal time'","volume":"43","author":"Hanley","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.jaad.2019.06.035_bib19","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"76","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.06.035_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2019.06.035_bib21","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jaad.2019.06.035_bib22","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/jamadermatol.2015.3579","article-title":"Time-dependent measurement of adverse events","volume":"151","author":"Hwang","year":"2015","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219310242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219310242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:53:08Z","timestamp":1759272788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219310242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0190962219310242"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.06.035","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.06.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}